Product Name:Bortezomib For Injection
Product Description:

Bortezomib for injection








Description


A white or similar white mass or powder.


?


Indications


Multiple Myeloma


(bortezomib) is indicated for the treatment of patients with multiple myeloma.


Mantle Cell Lymphoma


bortezomib is indicated for the treatment of patients with mantle cell lymphoma.


?


Dosage and administration


The recommended starting dose of bortezomib is 1.3 mg/m2 . bortezomib may be administered intravenously at a concentration of 1 mg/mL, or subcutaneously at a concentration of 2.5 mg/mL.


bortezomib retreatment may be considered for patients with multiple myeloma who had previously responded to treatment with bortezomib and who have relapsed at least 6 months after completing prior bortezomib treatment. Treatment may be started at the last tolerated dose.


When administered intravenously, bortezomib is administered as a 3 to 5 second bolus intravenous injection. bortezomib is for intravenous or subcutaneous use only. bortezomib should not be administered by any other route.


?


Side Effect?


>10%


Asthenia (61-65%),Nausea (61-65%),Diarrhea (51-55%),Anorexia (41-45%),Constipation (41-45%),Thrombocytopenia (41-45%),Peripheral neuropathy (IV: 16-41%; SC: 6-24%),Pyrexia (36-40%),Vomiting (36-40%),Anemia (31-35%),Arthralgia (26-30%),Headache (26-30%),Insomnia (26-30%),Limb pain (26-30%),Dizziness (21-25%),Dyspnea (21-25%),Edema (21-25%),Neutropenia (21-25%),Paresthesia (21-25%),Rash (21-25%),Cough (15-20%),Dehydration (15-20%),URI (15-20%),Rigors, grade 4 toxicity (10-15%)


Frequency Not Defined


Hypotension,Anxiety,Pain,Pruritis,Abdominal pain,Dyspepsia,Back pain,Bone pain,Myalgia,Muscle spasms,Herpes zoster,Pneumonia,Blurred vision


?


Contraindications


Hypersensitivity to any component or boron or mannitol; intrathecal administration


?


Precautions


Fatal events with inadvertent intrathecal administration reported


Syncope history


Dehydration


Use caution in hepatic impairment (reduce starting dose); monitor hepatic enzymes during treatment


Diabetes mellitus


Heart disease


High tumor load (risk of tumor lysis syndrome)


Acute respiratory syndromes have occurred; monitor closely for new or worsening symptoms


Risks of: CHF; severe lung disease (eg, ARDS, pneumonitis)


Closely monitor patients with high tumor burden


Acute diffuse infiltrative pulmonary disease, PRES (formerly RPLS)


Monitor complete blood counts regularly throughout treatment


Hypotension (antihypertensive dosages may need modification)


Nausea, diarrhea, constipation, and vomiting may require use of antiemetic and antidiarrheal medications or fluid replacement


Consider MRI imaging for onset of visual or neurological symptoms; discontinue therapy if suspected


Worsening of and development of cardiac failure reported; closely monitor patients with existing heart disease or risk factors for heart disease


Women should avoid becoming pregnant while on therapy; advise pregnant women of potential embryo-fetal harm


Associated with thrombocytopenia and neutropenia that follow a cyclical pattern with nadirs occurring following the last dose of each cycle and typically recovering prior to initiation of the subsequent cycle


.


Pharmacology


Mechanism of Action


Reversible inhibitor of chymotrypsin-like activity at the 26-S proteasome, which in turn causes cell cycle arrest and apoptosis


Absorption


Pleak plasma level: 509 ng/mL


Distribution


Protein bound: 83%


Vd: 498-1884 L/m2


Metabolism


Hepatic P450 enzyme CYP3A4 (major); also CYP1A2, 2C9, 2C19, 2D6 (minor)


Enzymes inhibited: CYP2C19


Elimination


Half-Life: 9-15 hr (single dose IV); 40-193 (multiple 1 mg/m2 doseing); 76-108 hr (multiple 1.3 mg/m2 dosing)





Related Keywords:


China bortezomib for Injection manufacturer,China bortezomib for Injection suppliers,bortezomib for Injection from China professional pharmaceutical factory,Oncology Drugs , Oncology Nursing Drug , Oncology And Supplementary Drug , Oncology Drugs Manufacturers , Oncology Drugs Suppliers , China Oncology Drugs , Bortezomib for Injection




Price:10.00
Product Website:[Misafirler Kayıt Olmadan Link Göremezler Lütfen Kayıt İçin Tıklayın ! ]
Company Description
Sundent Pharm Group
Address:ShanghaiShanghaiShanghaiSongjiangNo.1333 Xinlong Road, Shanghai.China.
Descption:Sundent Pharm Group (together with its subsidiaries, the Groupâ€) is one of the largest comprehensive manufacturing, marketing, promotion and channel management service provider dedicated to pharmaceutical products.? Since establishment in 2004, the Group has determined to apply global vision to local management, and has introduced a series of pharmaceutical products embedded with technologies that represent international advanced level to China, South America, Eastern European and south Asia countries.? As of Dec 2015, the company had portfolio of pharmaceutical products, covering pain management, cardiovascular, respiratory, gastroenterology, immunology and other therapeutic areas.? At the same time, the Group endeavors to uplift the market value of these brands.

With a global horizon and well-deserved creditability in international market development, the Group has established long-term and stable cooperation with a number of renowned Chinese pharmaceutical manufacturer leaders, independent product quality analysis and develop centers, Chinese SFDA etc., The network lays the foundation of the sustainable development of the company through the comprehensive and effective products introduction and cooperation.

Looking into the future, the Group is committed to build itself into a cutting-edge pharmaceutical manufacturing and marketing group company that grasps the sales channel and product pricing advantage in mainland China. We believe that, with rapid development of China's pharmaceutical industry, through an open-minded attitude, perspective new product introduction capability, accurate product marketing strategy, comprehensive marketing network and effective management system, Sundent Pharmaceutical Group is able to achieve our development target.
Registered Capital:50
EmployeeNum:50
Sundent Pharm Group
Contact:Tracy zhang
Telphone:86-21-67897115-0
Fax:86-21-67897115-802
Email:Sundent@aliyun.com
Company Website:[Misafirler Kayıt Olmadan Link Göremezler Lütfen Kayıt İçin Tıklayın ! ]